Citadel Advisors
JUNO

Citadel Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Citadel Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-224,352
Closed -$10.3M – 9174
2017
Q4 		$10.3M Sell
224,352
-767
-0.3% -$38.3K 0.01% 1710
2017
Q3 		$10.1M Buy
225,119
+96,891
+76% +$3.3M 0.01% 1594
2017
Q2 		$3.83M Buy
+128,228
New +$3.16M ﹤0.01% 2400
2017
Q1 		– Sell
-43,019
Closed -$923K – 8417
2016
Q4 		$811K Buy
+43,019
New +$1.05M ﹤0.01% 4161
2016
Q3 		– Sell
-41,119
Closed -$1.28M – 8119
2016
Q2 		$1.58M Buy
41,119
+19,495
+90% +$809K ﹤0.01% 2987
2016
Q1 		$824K Buy
21,624
+17,970
+492% +$626K ﹤0.01% 3710
2015
Q4 		$161K Sell
3,654
-498
-12% -$24.7K ﹤0.01% 6102
2015
Q3 		$169K Sell
4,152
-354,859
-99% -$15.6M ﹤0.01% 6367
2015
Q2 		$19.1M Buy
359,011
+351,157
+4,471% +$18.6M 0.02% 1033
2015
Q1 		$476K Sell
7,854
-42,983
-85% -$2.09M ﹤0.01% 4979
2014
Q4 		$2.65M Buy
+50,837
New +$2.28M ﹤0.01% 2604

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Citadel Advisors's JUNO Position: Q1 2018 in Review

Citadel Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 224,352 shares — an estimated $10.3M sold.

Citadel Advisors first reported a position in JUNO in Q4 2014 and held it in 11 quarters. The position peaked at $19.1M in Q2 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Citadel Advisors reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Citadel Advisors sold 224,352 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $10.3M.
  • Citadel Advisors first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 11 quarters.
  • Citadel Advisors's Juno Therapeutics, Inc. position peaked at $19.1M in Q2 2015.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Citadel Advisors's 13F filing for Q1 2018, filed 11 May 2018.